Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT04492033
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
- Conditions
- Interventions
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 105
- Registration Number
- NCT04481204
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04453930
- Locations
- 🇨🇳
Beijing Union Medical College Hospital, Beijing, China
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 77
- Registration Number
- NCT04447092
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 222
- Registration Number
- NCT04443543
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Cencer, Shanghai, Shanghai, China
FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)
- Conditions
- Interventions
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 326
- Registration Number
- NCT04442984
- Locations
- 🇷🇺
Blokhin's Russian Cancer Research Center, Moscow, Russian Federation
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT04411524
- Locations
- 🇨🇳
Zhen Zhang, Shanghai, Shanghai, China
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT04411537
- Locations
- 🇨🇳
Zhen Zhang, Shanghai, Shanghai, China
FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 538
- Registration Number
- NCT04393584
- Locations
- 🇷🇺
Aleksei Kalinin, Moscow, Russian Federation
A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 210
- Registration Number
- NCT04394598
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.